Corporate-backed food safety testing company Roka Bioscience said it had secured financing worth $47.5m for its latest round of funding.
US-based Roka said on Friday it had closed $27.5m of the series D round and expected to close the remaining $20m later this year. Backers of the latest round included investment firm Aisling Capital, venture funds OrbiMed Advisors, New Enterprise Associates, and TPG Biotech, the specialist investment unit of the private equity firm.
In July last year Roka formalised its spin-off from its former parent Gen-Probe, a Nasdaq-listed molecular diagnostics company, when it raised $20m in a series C, in which Gen-Probe also invested. Roka has now raised $104.7m since it was founded in September 2009.
Josh Bilenker, a partner at Aisling, will join Roka’s board.